AGL

Company Overview — What Does agilon health, inc. Do?

agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. As of December 31, 2021, it served approximately 238,000 senior members, which included 186,300 medicare advantage members and 51,700 medicare fee-for-service beneficiaries. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas. agilon health, inc. (AGL) is classified as a micro-cap stock in the Healthcare sector. The company is led by CEO Steven J. Sell and employs approximately 650 people. With a market capitalization of $162M, AGL is one of the notable companies in the Healthcare sector.

agilon health, inc. (AGL) Stock Rating — Reduce (April 2026)

As of April 2026, agilon health, inc. receives a Reduce rating with a composite score of 30.4/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.AGL ranks #3,166 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, agilon health, inc. ranks #473 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

AGL Stock Price and 52-Week Range

agilon health, inc. (AGL) currently trades at $19.02. The stock lost $0.82 (4.1%) in the most recent trading session. The 52-week high for AGL is $6.08, which means the stock is currently trading 212.8% from its annual peak. The 52-week low is $0.34, putting the stock 5535.6% above its annual trough. Recent trading volume was 339K shares, suggesting relatively thin trading activity.

Is AGL Overvalued or Undervalued? — Valuation Analysis

agilon health, inc. (AGL) carries a value factor score of 8/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.17x, versus the sector average of 2.75x. The price-to-sales ratio is 0.05x, compared to 1.66x for the average Healthcare stock.

At current multiples, agilon health, inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

agilon health, inc. Profitability — ROE, Margins, and Quality Score

agilon health, inc. (AGL) earns a quality factor score of 20/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -252.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -25.2% versus the sector average of -33.1%.

On a margin basis, agilon health, inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -7.0% (sector: -66.1%). Net profit margin stands at -5.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -3.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

AGL Debt, Balance Sheet, and Financial Health

agilon health, inc. has a debt-to-equity ratio of 28.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 1.02x, suggesting adequate working capital coverage. Total debt on the balance sheet is $35M. Cash and equivalents stand at $172M.

AGL has a beta of 0.14, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for agilon health, inc. is 26/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

agilon health, inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, agilon health, inc. reported revenue of $5.81B. Net income for the quarter was $-320M. Gross margin was 100.0%. Operating income came in at $-403M.

In FY 2025, agilon health, inc. reported revenue of $5.93B. Net income for the quarter was $-391M. Revenue grew -2.1% year-over-year compared to FY 2024. Operating income came in at $-463M.

In Q3 2025, agilon health, inc. reported revenue of $1.44B. Net income for the quarter was $-110M. Revenue grew -1.1% year-over-year compared to Q3 2024. Operating income came in at $-131M.

In Q2 2025, agilon health, inc. reported revenue of $1.39B. Net income for the quarter was $-104M. Revenue grew -5.9% year-over-year compared to Q2 2024. Operating income came in at $-116M.

Over the past 8 quarters, agilon health, inc. has demonstrated a growth trajectory, with revenue expanding from $1.48B to $5.81B. Investors analyzing AGL stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

AGL Dividend Yield and Income Analysis

agilon health, inc. (AGL) does not currently pay a dividend. This is common among smaller companies in the Healthcare industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

AGL Momentum and Technical Analysis Profile

agilon health, inc. (AGL) has a momentum factor score of 41/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 35/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 69/100 reflects moderate short selling activity.

AGL vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, agilon health, inc. (AGL) ranks #473 out of 838 stocks based on the Blank Capital composite score. This places AGL in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing AGL against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full AGL vs S&P 500 (SPY) comparison to assess how agilon health, inc. stacks up against the broader market across all factor dimensions.

AGL Next Earnings Date

No upcoming earnings date has been announced for agilon health, inc. (AGL) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy AGL? — Investment Thesis Summary

The quantitative profile for agilon health, inc. suggests caution. The quality score of 20/100 flags below-average profitability. The value score of 8/100 indicates premium valuation. High volatility (stability score 26/100) increases portfolio risk.

In summary, agilon health, inc. (AGL) earns a Reduce rating with a composite score of 30.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on AGL stock.

Related Resources for AGL Investors

Explore more research and tools: AGL vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare AGL head-to-head with peers: AGL vs AZN, AGL vs SLGL, AGL vs VMD.